74 related articles for article (PubMed ID: 18092518)
1. Bioluminescence imaging of vascular endothelial growth factor promoter activity in murine mammary tumorigenesis.
Faley SL; Takahashi K; Crooke CE; Beckham JT; Tomemori T; Shappell SB; Jansen ED; Takahashi T
Mol Imaging; 2007; 6(5):331-9. PubMed ID: 18092518
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive indirect imaging of vascular endothelial growth factor gene expression using bioluminescence imaging in living transgenic mice.
Wang Y; Iyer M; Annala A; Wu L; Carey M; Gambhir SS
Physiol Genomics; 2006 Jan; 24(2):173-80. PubMed ID: 16410544
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE
Oncogene; 2005 Jan; 24(5):790-800. PubMed ID: 15592523
[TBL] [Abstract][Full Text] [Related]
4. Hyperplasia and impaired involution in the mammary gland of transgenic mice expressing human FGF4.
Morini M; Astigiano S; Mora M; Ricotta C; Ferrari N; Mantero S; Levi G; Rossini M; Barbieri O
Oncogene; 2000 Dec; 19(52):6007-14. PubMed ID: 11146552
[TBL] [Abstract][Full Text] [Related]
5. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression.
Zhang L; Yu D; Hu M; Xiong S; Lang A; Ellis LM; Pollock RE
Cancer Res; 2000 Jul; 60(13):3655-61. PubMed ID: 10910082
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts.
Hartman J; Lindberg K; Morani A; Inzunza J; Ström A; Gustafsson JA
Cancer Res; 2006 Dec; 66(23):11207-13. PubMed ID: 17145865
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive bioluminescence imaging of normal and spontaneously transformed prostate tissue in mice.
Lyons SK; Lim E; Clermont AO; Dusich J; Zhu L; Campbell KD; Coffee RJ; Grass DS; Hunter J; Purchio T; Jenkins D
Cancer Res; 2006 May; 66(9):4701-7. PubMed ID: 16651422
[TBL] [Abstract][Full Text] [Related]
8. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model.
Hsieh CL; Xie Z; Yu J; Martin WD; Datta MW; Wu GJ; Chung LW
Prostate; 2007 May; 67(7):685-91. PubMed ID: 17342752
[TBL] [Abstract][Full Text] [Related]
9. Real-time imaging of beta-lactoglobulin-targeted luciferase activity in the mammary glands of transgenic mice.
Barash I; Reichenstein M
Mol Reprod Dev; 2002 Jan; 61(1):42-8. PubMed ID: 11774374
[TBL] [Abstract][Full Text] [Related]
10. VEGF enhances pulmonary vasculogenesis and disrupts lung morphogenesis in vivo.
Zeng X; Wert SE; Federici R; Peters KG; Whitsett JA
Dev Dyn; 1998 Mar; 211(3):215-27. PubMed ID: 9520109
[TBL] [Abstract][Full Text] [Related]
11. VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanisms.
Schoeffner DJ; Matheny SL; Akahane T; Factor V; Berry A; Merlino G; Thorgeirsson UP
Lab Invest; 2005 May; 85(5):608-23. PubMed ID: 15765121
[TBL] [Abstract][Full Text] [Related]
12. NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice.
Krane IM; Leder P
Oncogene; 1996 Apr; 12(8):1781-8. PubMed ID: 8622899
[TBL] [Abstract][Full Text] [Related]
13. [Adenovirus-mediated double suicide gene selectively kills breast cancer MCF-7 cells in vitro].
Kong H; Huang ZH; Li Q; Yang LC; Yu JL; Li Z
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jun; 28(6):907-10. PubMed ID: 18583225
[TBL] [Abstract][Full Text] [Related]
14. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner.
López-Ocejo O; Viloria-Petit A; Bequet-Romero M; Mukhopadhyay D; Rak J; Kerbel RS
Oncogene; 2000 Sep; 19(40):4611-20. PubMed ID: 11030150
[TBL] [Abstract][Full Text] [Related]
15. Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells.
Galiano RD; Tepper OM; Pelo CR; Bhatt KA; Callaghan M; Bastidas N; Bunting S; Steinmetz HG; Gurtner GC
Am J Pathol; 2004 Jun; 164(6):1935-47. PubMed ID: 15161630
[TBL] [Abstract][Full Text] [Related]
16. Identification of promoter regions involved in cell- and developmental stage-specific osteopontin expression in bone, kidney, placenta, and mammary gland: an analysis of transgenic mice.
Higashibata Y; Sakuma T; Kawahata H; Fujihara S; Moriyama K; Okada A; Yasui T; Kohri K; Kitamura Y; Nomura S
J Bone Miner Res; 2004 Jan; 19(1):78-88. PubMed ID: 14753740
[TBL] [Abstract][Full Text] [Related]
17. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
Song Y; Shen K; Yu JR
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307
[TBL] [Abstract][Full Text] [Related]
18. Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein.
Zhang D; Li B; Shi J; Zhao L; Zhang X; Wang C; Hou S; Qian W; Kou G; Wang H; Guo Y
Cancer Res; 2010 Mar; 70(6):2495-503. PubMed ID: 20197464
[TBL] [Abstract][Full Text] [Related]
19. VEGF-DT385 toxin conjugate inhibits mammary adenocarcinoma development in a transgenic mouse model of spontaneous tumorigenesis.
Wild R; Yokoyama Y; Dings RP; Ramakrishnan S
Breast Cancer Res Treat; 2004 May; 85(2):161-71. PubMed ID: 15111774
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
Ebos JM; Lee CR; Bogdanovic E; Alami J; Van Slyke P; Francia G; Xu P; Mutsaers AJ; Dumont DJ; Kerbel RS
Cancer Res; 2008 Jan; 68(2):521-9. PubMed ID: 18199548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
